10:41 AM
 | 
Oct 26, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Innovent raises $421M in Hong Kong IPO

Cancer and autoimmune company Innovent Biologics Inc. (HKSE:1801) priced its IPO on the Hong Kong stock exchange on Oct. 24, raising HK$3.3 billion ($421 million).

Innovent sold 236.4 million shares at HK$13.98, near the top of its proposed range of HK$12.50-HK$14. The offering values Innovent at $2 billion....

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >